Making the Call in Type 2 Diabetes

GLP-1 Receptor Agonists and Reducing Stroke Risk

Cardiovascular disease (CVD) is the leading cause of death among patients with type 2 diabetes (T2D). Among the potential cardiovascular complications of T2DM, stroke is a particularly high risk for patients, especially given the aging population. Increasing rates of diabetes, hypertension, and obesity are also placing a larger population of younger patients at risk for stroke. Some antidiabetic therapies, including certain glucagon-like peptide-1 (GLP-1) receptor agonists, can reduce the CVD risks in patients with T2D and contribute to secondary prevention. Expert faculty discussions in this Phone-a-Friend series will address specific challenge related to the management of patients with T2D, the risk of stroke, and the roles of GLP-1 receptor agonists.

This series is jointly provided by Global Education Group and Integritas Communications. 

 

This series is supported by an educational grant from Novo Nordisk Inc.

GLP-1 Receptor Agonists and Cardiovascular Risks

Module 1

Kathleen Dungan, MD, MPH & Charles P. Vega, MD, FAAFP
MODULE 1
Begin Activity

credit amount 0.25

credit type CME/CE

expiration 09/29/2023

Educating Patients With T2D About Stroke Risk

Module 2

Eileen Egan, DNP, FNP-C, BC-ADM, CDCES, FADCES & Charles P. Vega, MD, FAAFP
MODULE 2
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 10/18/2023

Image Webcast Series
Managing Patients With T2D Who Are Recovering From A Stroke

Module 3

J. David Spence C.M., MD, FRCPC, FAHA & Charles P. Vega, MD, FAAFP
MODULE 3
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 11/11/2023

Image Webcast Series
The Pathophysiology of T2D and Stroke

Module 4

J. David Spence C.M., M.D., FRCPC, FAHA & Charles P. Vega, MD, FAAFP
MODULE 4
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 11/30/2023

Resource

Making the Call in Type 2 Diabetes

GLP-1 Receptor Agonists and Reducing Stroke Risk